董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Bencich | 男 | Director and Chief Executive Officer | 43 | 88.37万美元 | 未持股 | 2021-03-15 |
| Bridget Martell | 女 | Director | 55 | 未披露 | 未持股 | 2021-03-15 |
| Richard Stewart | 男 | Director, Executive Chairman and Chairman of the Board | 62 | 103.25万美元 | 未持股 | 2021-03-15 |
| Donald Joseph | 男 | Director | 67 | 8.37万美元 | 未持股 | 2021-03-15 |
| Jay Moyes | 男 | Director | 67 | 6.62万美元 | 未持股 | 2021-03-15 |
| Cindy Jacobs | 女 | Director, President and Chief Medical Officer | 63 | 77.39万美元 | 未持股 | 2021-03-15 |
| Martin Mattingly | 男 | Director | 64 | 6.87万美元 | 未持股 | 2021-03-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Bencich | 男 | Director and Chief Executive Officer | 43 | 88.37万美元 | 未持股 | 2021-03-15 |
| Richard Stewart | 男 | Director, Executive Chairman and Chairman of the Board | 62 | 103.25万美元 | 未持股 | 2021-03-15 |
| Anthony Clarke | 男 | Chief Scientific Officer | 65 | 未披露 | 未持股 | 2021-03-15 |
| Jerry Wan | 男 | Principal Accounting Officer | 39 | 未披露 | 未持股 | 2021-03-15 |
| Cindy Jacobs | 女 | Director, President and Chief Medical Officer | 63 | 77.39万美元 | 未持股 | 2021-03-15 |
董事简历
中英对照 | 中文 | 英文- John Bencich
-
John Bencich，2014年8月以来，他一直担任我们的副总裁兼首席财务官。加入我们之前，他曾任职Integrated Diagnostics公司（分子诊断公司），在那里他担任首席财务官（从2012年9月到2014年8月）。加入Integrated Diagnostics公司之前，他曾担任Allozyne公司的首席财务官（2011年7月以来）。他曾担任独立顾问（2010年11月至加入Allozyne公司）。他曾担任Trubion Pharmaceuticals公司（生物科技公司）的副总裁、首席财务官、财务主管（从2009年11月到2010年10月公司被Emergent BioSolutions公司收购）。他曾担任Trubion公司的高级财务会计董事（2007年5月至2009年11月）。2004年9月至2007年4月，他曾任职Onyx Software Corporation（软件公司），在那里他最后担任财务主管兼公司总会计师。从1999年到2004年，他曾担任Ernst & Young公司（国际专业服务公司）的职员，在那里他最后担任经理。他持有the University of San Diego的会计学士学位，以及Seattle University的工商管理硕士学位。他持有the State of Washington的注册会计师执照，目前拥有一个活跃的许可证。
John Bencich has served as our Chief Executive Officer and member of the Board of Directors since September 2020. Previously, Mr. Bencich served as our Vice President and Chief Financial Officer since August 2014 and as our Executive Vice President and Chief Operating Officer since August 2017. Mr. Bencich joined us from Integrated Diagnostics, Inc., a molecular diagnostics company, where he served as Chief Financial Officer from September 2012 to August 2014. Prior to joining Integrated Diagnostics, he served as Chief Financial Officer of Allozyne, Inc. since July 2011. Mr. Bencich was an independent consultant from November 2010 until he joined Allozyne. He served as the Vice President, Chief Financial Officer and Treasurer of Trubion Pharmaceuticals, Inc., a publicly traded biotechnology company, from November 2009 until its acquisition by Emergent BioSolutions Inc. in October 2010. Mr. Bencich served as Trubion’s Senior Director of Finance and Accounting from May 2007 through November 2009. From September 2004 to April 2007 Mr. Bencich was an employee of Onyx Software Corporation, a publicly traded software company, where he last served as Director of Finance and Corporate Controller. From 1999 to 2004 Mr. Bencich was an employee of Ernst & Young LLP, an international professional services firm, where he last served as a manager. Mr. Bencich received a B.A. in Accountancy from the University of San Diego and an M.B.A. from Seattle University. Mr. Bencich received his Certified Public Accountant Certification from the State of Washington and held an active license for 17 years. - John Bencich，2014年8月以来，他一直担任我们的副总裁兼首席财务官。加入我们之前，他曾任职Integrated Diagnostics公司（分子诊断公司），在那里他担任首席财务官（从2012年9月到2014年8月）。加入Integrated Diagnostics公司之前，他曾担任Allozyne公司的首席财务官（2011年7月以来）。他曾担任独立顾问（2010年11月至加入Allozyne公司）。他曾担任Trubion Pharmaceuticals公司（生物科技公司）的副总裁、首席财务官、财务主管（从2009年11月到2010年10月公司被Emergent BioSolutions公司收购）。他曾担任Trubion公司的高级财务会计董事（2007年5月至2009年11月）。2004年9月至2007年4月，他曾任职Onyx Software Corporation（软件公司），在那里他最后担任财务主管兼公司总会计师。从1999年到2004年，他曾担任Ernst & Young公司（国际专业服务公司）的职员，在那里他最后担任经理。他持有the University of San Diego的会计学士学位，以及Seattle University的工商管理硕士学位。他持有the State of Washington的注册会计师执照，目前拥有一个活跃的许可证。
- John Bencich has served as our Chief Executive Officer and member of the Board of Directors since September 2020. Previously, Mr. Bencich served as our Vice President and Chief Financial Officer since August 2014 and as our Executive Vice President and Chief Operating Officer since August 2017. Mr. Bencich joined us from Integrated Diagnostics, Inc., a molecular diagnostics company, where he served as Chief Financial Officer from September 2012 to August 2014. Prior to joining Integrated Diagnostics, he served as Chief Financial Officer of Allozyne, Inc. since July 2011. Mr. Bencich was an independent consultant from November 2010 until he joined Allozyne. He served as the Vice President, Chief Financial Officer and Treasurer of Trubion Pharmaceuticals, Inc., a publicly traded biotechnology company, from November 2009 until its acquisition by Emergent BioSolutions Inc. in October 2010. Mr. Bencich served as Trubion’s Senior Director of Finance and Accounting from May 2007 through November 2009. From September 2004 to April 2007 Mr. Bencich was an employee of Onyx Software Corporation, a publicly traded software company, where he last served as Director of Finance and Corporate Controller. From 1999 to 2004 Mr. Bencich was an employee of Ernst & Young LLP, an international professional services firm, where he last served as a manager. Mr. Bencich received a B.A. in Accountancy from the University of San Diego and an M.B.A. from Seattle University. Mr. Bencich received his Certified Public Accountant Certification from the State of Washington and held an active license for 17 years.
- Bridget Martell
-
Bridget Martell，她曾监管许多制药公司（包括Purdue Pharma公司，以及Pfizer Worldwide公司的生物制药企业的几个业务部门）的产品开发活动。任职Purdue Pharma公司期间（从2011年10月到2013年4月），她曾领导并建立一个新的医疗事务组织，并支持在线和开发药物组合。任职Purdue Pharma公司之前，她曾担任Pfizer公司的生物仿制药品医疗负责人，在那里她负责临床开发和医疗事务活动（从2010年8月到2011年8月）。她也曾担任Pfizer公司的生物制药企业的其它业务单位的高级临床开发职务。最近，她曾担任BAM Consultants公司（为广泛的专业制药公司提供临床开发和医疗事务咨询服务）的创始人兼董事总经理（从2013年4月到2015年1月）。
Bridget Martell has served as a director since March 2021. Dr. Martell has served as Acting Chief Medical Officer of Nobias Therapeutics from August 2020 to present and for Verseau Therapeutics since December 2020. In October 2017 Dr. Martell began working with Kura Oncology, a clinical-stage biopharmaceutical company, where she served as VP, Clinical Development from October 2017 to January 2020 as Acting Chief Medical Officer from January 2020 to August 2020 and as Senior Scientific Advisor since August 2020. Concurrently, Dr. Martell served as Chief Medical Officer of RRD International, a boutique Contract Research Organization from April 2018 to January 2020. From January 2015 to September 2017 Dr. Martell served as Senior Vice President, New Product Development at Juniper Pharmaceuticals, a publicly-held specialty pharmaceuticals company. From October 2011 to April 2013 she was Executive Director, Head Medical Affairs at Purdue Pharma L.P., a privately-held pharmaceutical company. Previous to that, Dr. Martell held leadership roles of increasing responsibility at Pfizer, Inc., a publicly-held biopharmaceutical company from 2005 to 2011. Dr. Martell earned her B.S. in microbiology from Cornell University, her M.A. in molecular immunology from Boston University and her M.D. from the Chicago Medical School. She completed her internship and residency in internal medicine and was an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University. Dr. Martell is board certified in both internal and addiction medicine. - Bridget Martell，她曾监管许多制药公司（包括Purdue Pharma公司，以及Pfizer Worldwide公司的生物制药企业的几个业务部门）的产品开发活动。任职Purdue Pharma公司期间（从2011年10月到2013年4月），她曾领导并建立一个新的医疗事务组织，并支持在线和开发药物组合。任职Purdue Pharma公司之前，她曾担任Pfizer公司的生物仿制药品医疗负责人，在那里她负责临床开发和医疗事务活动（从2010年8月到2011年8月）。她也曾担任Pfizer公司的生物制药企业的其它业务单位的高级临床开发职务。最近，她曾担任BAM Consultants公司（为广泛的专业制药公司提供临床开发和医疗事务咨询服务）的创始人兼董事总经理（从2013年4月到2015年1月）。
- Bridget Martell has served as a director since March 2021. Dr. Martell has served as Acting Chief Medical Officer of Nobias Therapeutics from August 2020 to present and for Verseau Therapeutics since December 2020. In October 2017 Dr. Martell began working with Kura Oncology, a clinical-stage biopharmaceutical company, where she served as VP, Clinical Development from October 2017 to January 2020 as Acting Chief Medical Officer from January 2020 to August 2020 and as Senior Scientific Advisor since August 2020. Concurrently, Dr. Martell served as Chief Medical Officer of RRD International, a boutique Contract Research Organization from April 2018 to January 2020. From January 2015 to September 2017 Dr. Martell served as Senior Vice President, New Product Development at Juniper Pharmaceuticals, a publicly-held specialty pharmaceuticals company. From October 2011 to April 2013 she was Executive Director, Head Medical Affairs at Purdue Pharma L.P., a privately-held pharmaceutical company. Previous to that, Dr. Martell held leadership roles of increasing responsibility at Pfizer, Inc., a publicly-held biopharmaceutical company from 2005 to 2011. Dr. Martell earned her B.S. in microbiology from Cornell University, her M.A. in molecular immunology from Boston University and her M.D. from the Chicago Medical School. She completed her internship and residency in internal medicine and was an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University. Dr. Martell is board certified in both internal and addiction medicine.
- Richard Stewart
-
Richard Stewart自2017年8月起担任公司董事长、首席执行官和董事。在我们与Achieve Life Science，Inc.合并或合并之前，Stewart先生自2015年5月Achieve Life Science，Inc.成立以来一直担任其董事长兼董事。Stewart自2009年起担任Ricanto Limited（一家制药资产优化公司）创始人和董事。Stewart先生自2016年以来一直担任Renown Pharma Limited的董事长兼首席执行官，该公司是一家专注于帕金森氏症的中枢神经系统公司。在此之前，Stewart先生于2009年担任单一用途中枢神经系统公司Huxley Pharmaceuticals，Inc.的董事长兼首席执行官，在此之前，Huxley Pharmaceuticals，Inc.被Biomarin PharmaceuticalInc.收购Stewart从2013年到2014年担任Brabant Pharma Limited（一家单一目的中枢神经系统公司）首席执行官。从2000年到2007年，他是Amarin Corporation Plc（一家中枢神经系统公司，专注于帕金森氏症和亨廷顿氏症）的联合创始人兼首席执行官。Stewart先生是SkyePharma plc（一家药物输送公司，专门从事控释制剂）的联合创始人和首席财务官，后来担任首席商务官，并从1995年到1998年担任该职位。Stewart先生持有巴斯大学（University of Bath）工商管理理学学士学位。
Richard Stewart has served as our Executive Chairman since September 2020 and our Chairman of the Board, and a director since the consummation of the Merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. in August 2017 the “Merger”. Previously, Mr. Stewart served as Chief Executive Officer from the Merger to September 2020 and was Chairman and a director of Achieve Life Science, Inc., from its founding in May 2015 through the Merger. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009 prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to its acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath. - Richard Stewart自2017年8月起担任公司董事长、首席执行官和董事。在我们与Achieve Life Science，Inc.合并或合并之前，Stewart先生自2015年5月Achieve Life Science，Inc.成立以来一直担任其董事长兼董事。Stewart自2009年起担任Ricanto Limited（一家制药资产优化公司）创始人和董事。Stewart先生自2016年以来一直担任Renown Pharma Limited的董事长兼首席执行官，该公司是一家专注于帕金森氏症的中枢神经系统公司。在此之前，Stewart先生于2009年担任单一用途中枢神经系统公司Huxley Pharmaceuticals，Inc.的董事长兼首席执行官，在此之前，Huxley Pharmaceuticals，Inc.被Biomarin PharmaceuticalInc.收购Stewart从2013年到2014年担任Brabant Pharma Limited（一家单一目的中枢神经系统公司）首席执行官。从2000年到2007年，他是Amarin Corporation Plc（一家中枢神经系统公司，专注于帕金森氏症和亨廷顿氏症）的联合创始人兼首席执行官。Stewart先生是SkyePharma plc（一家药物输送公司，专门从事控释制剂）的联合创始人和首席财务官，后来担任首席商务官，并从1995年到1998年担任该职位。Stewart先生持有巴斯大学（University of Bath）工商管理理学学士学位。
- Richard Stewart has served as our Executive Chairman since September 2020 and our Chairman of the Board, and a director since the consummation of the Merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. in August 2017 the “Merger”. Previously, Mr. Stewart served as Chief Executive Officer from the Merger to September 2020 and was Chairman and a director of Achieve Life Science, Inc., from its founding in May 2015 through the Merger. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009 prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to its acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath.
- Donald Joseph
-
Donald Joseph自2017年8月起担任董事。他目前担任生物制药和全球卫生组织的顾问和顾问。他拥有超过二十年的生物制药行业经验，包括担任全球健康非营利组织的高级管理职务。Joseph先生于2013年6月至2015年11月担任Humanigen，Inc.（前身为KaloBiosPharmaceuticals，Inc.，一家公开上市公司）的首席法务官兼董事会秘书。任职Humanigen公司之前，他曾担任Bio Ventures for Global Health（BVGH）的首席执行官（从2012年2月到11月），以及首席运营官（从2010年4月到2012年1月）。他是BVGH董事会的前任主席兼现任秘书和成员。他也曾担任the Institute for Oneworld Health（一个非营利药物开发公司）的首席运营官。他此前曾担任上市生物制药公司（包括Abgenix公司和Renovis公司）的总法律顾问、公司秘书和其他高级管理职务。在进入生命科学行业之前，Joseph先生在主要公司从事了多年的商法执业，包括在世界上最大的律师事务所之一Baker&McKenzie担任国际合伙人。他以优异成绩获得德克萨斯大学法学院（the University of Texas School of Law）的法学博士学位。
Donald Joseph has served as a director since August 2017. He currently serves as Chief Legal Officer and Secretary of Acer Therapeutics Inc., a publicly listed pharmaceutical company, since April 2018. He previously served as an advisor and consultant to biopharmaceutical and global health organizations. He has over twenty years of biopharmaceutical industry experience, including senior management positions in global health non-profit organizations. Mr. Joseph served as the Chief Legal Officer and Board Secretary of Humanigen, Inc. previously known as KaloBios Pharmaceuticals, Inc., a publicly listed company, from June 2013 to November 2015. Prior to Humanigen/KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health, or BVGH, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is a former Chairman and Secretary and director of BVGH. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. He received his J.D. degree from the University of Texas School of Law, with honors. - Donald Joseph自2017年8月起担任董事。他目前担任生物制药和全球卫生组织的顾问和顾问。他拥有超过二十年的生物制药行业经验，包括担任全球健康非营利组织的高级管理职务。Joseph先生于2013年6月至2015年11月担任Humanigen，Inc.（前身为KaloBiosPharmaceuticals，Inc.，一家公开上市公司）的首席法务官兼董事会秘书。任职Humanigen公司之前，他曾担任Bio Ventures for Global Health（BVGH）的首席执行官（从2012年2月到11月），以及首席运营官（从2010年4月到2012年1月）。他是BVGH董事会的前任主席兼现任秘书和成员。他也曾担任the Institute for Oneworld Health（一个非营利药物开发公司）的首席运营官。他此前曾担任上市生物制药公司（包括Abgenix公司和Renovis公司）的总法律顾问、公司秘书和其他高级管理职务。在进入生命科学行业之前，Joseph先生在主要公司从事了多年的商法执业，包括在世界上最大的律师事务所之一Baker&McKenzie担任国际合伙人。他以优异成绩获得德克萨斯大学法学院（the University of Texas School of Law）的法学博士学位。
- Donald Joseph has served as a director since August 2017. He currently serves as Chief Legal Officer and Secretary of Acer Therapeutics Inc., a publicly listed pharmaceutical company, since April 2018. He previously served as an advisor and consultant to biopharmaceutical and global health organizations. He has over twenty years of biopharmaceutical industry experience, including senior management positions in global health non-profit organizations. Mr. Joseph served as the Chief Legal Officer and Board Secretary of Humanigen, Inc. previously known as KaloBios Pharmaceuticals, Inc., a publicly listed company, from June 2013 to November 2015. Prior to Humanigen/KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health, or BVGH, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is a former Chairman and Secretary and director of BVGH. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. He received his J.D. degree from the University of Texas School of Law, with honors.
- Jay Moyes
-
Jay Moyes自2017年8月起担任董事。Moyes先生自2006年5月起担任OsirisTherapeutics，Inc.董事会成员，自2011年起担任Biocardia，Inc.董事会成员，自2012年起担任PumaBiotechnology，Inc.董事会成员。他也曾担任Integrated Diagnostics公司（私人持有的分子诊断公司）的董事会成员（2011年至2016年）。Moyes先生曾担任Amedica Corporation（一家公开上市的骨科公司）的董事会成员，并于2013年至2014年担任其首席财务官。从2008年到2009年，Moyes先生还担任CareDx的首席财务官，这是一家上市的心血管诊断公司。在此之前，从1993年到2007年11月退休，他担任MyriadGenetics，Inc.（一家上市的分子诊断公司）的首席财务官。从1991年到1993年，Moyes先生担任Genmark，Inc.的财务Vice President和首席财务官，该公司是一家私人持有的动物遗传学公司。Moyes从1979年到1991年在毕马威会计师事务所（KPMG）担任多个职位。他也曾担任the Utah Life Science Association的董事会成员（从1999年到2006年）。Moyes先生拥有犹他大学（University of Utah）的工商管理硕士学位，韦伯州立大学（Weber State University）的经济学文学学士学位，之前是一名注册会计师。
Jay Moyes has served as our Chief Financial Officer since March 2020. Mr. Moyes has been a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, since August 2017. He has been a member of the board of directors of Puma Biotechnology, Inc., a public biotherapeutics company focused on oncology, since April 2012. He has been a member of the board of directors of Biocardia, Inc., a publicly held cardiovascular regenerative medicine company, since January 2011. Mr. Moyes served as a member of the board of directors of Predictive Technology Group, Inc., a public molecular diagnostics and regenerative medicine company, from February 2019 to December 2019. Mr. Moyes was a director of Integrated Diagnostics, Inc., a privately held molecular diagnostics company from March 2011 to November 2016. Mr. Moyes was a member of the board of directors of Osiris Therapeutics, Inc., a public bio-surgery company, from May 2006 until December 2017 and Amedica Corporation, a public orthopedic implant company, from November 2012 to August 2014. He served as Chief Financial Officer of Amedica from October 2013 to August 2014 where he was responsible for developing and executing the company’s financial strategy. From May 2008 through July 2009 Mr. Moyes served as the Chief Financial Officer of XDx, Inc. now CareDx, Inc., a privately held molecular diagnostics company. In that role, he orchestrated the company’s right-sizing strategy. Prior to that, Mr. Moyes served as the Chief Financial Officer of Myriad Genetics, Inc., a public healthcare diagnostics company, from June 1996 until November 2007 and as its Vice President of Finance from July 1993 until May 1996 where he led the financial team as it transitioned from a small private company to a publicly held enterprise. From 1991 to 1993 Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. In that role he established the company’s financial infrastructure. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991 most recently as a Senior Manager. At KPMG LLP, he was primarily responsible for conducting financial audits of high-tech and biotech clients. Mr. Moyes also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 through 2006. He holds an M.B.A. from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certified Public Accountant. - Jay Moyes自2017年8月起担任董事。Moyes先生自2006年5月起担任OsirisTherapeutics，Inc.董事会成员，自2011年起担任Biocardia，Inc.董事会成员，自2012年起担任PumaBiotechnology，Inc.董事会成员。他也曾担任Integrated Diagnostics公司（私人持有的分子诊断公司）的董事会成员（2011年至2016年）。Moyes先生曾担任Amedica Corporation（一家公开上市的骨科公司）的董事会成员，并于2013年至2014年担任其首席财务官。从2008年到2009年，Moyes先生还担任CareDx的首席财务官，这是一家上市的心血管诊断公司。在此之前，从1993年到2007年11月退休，他担任MyriadGenetics，Inc.（一家上市的分子诊断公司）的首席财务官。从1991年到1993年，Moyes先生担任Genmark，Inc.的财务Vice President和首席财务官，该公司是一家私人持有的动物遗传学公司。Moyes从1979年到1991年在毕马威会计师事务所（KPMG）担任多个职位。他也曾担任the Utah Life Science Association的董事会成员（从1999年到2006年）。Moyes先生拥有犹他大学（University of Utah）的工商管理硕士学位，韦伯州立大学（Weber State University）的经济学文学学士学位，之前是一名注册会计师。
- Jay Moyes has served as our Chief Financial Officer since March 2020. Mr. Moyes has been a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, since August 2017. He has been a member of the board of directors of Puma Biotechnology, Inc., a public biotherapeutics company focused on oncology, since April 2012. He has been a member of the board of directors of Biocardia, Inc., a publicly held cardiovascular regenerative medicine company, since January 2011. Mr. Moyes served as a member of the board of directors of Predictive Technology Group, Inc., a public molecular diagnostics and regenerative medicine company, from February 2019 to December 2019. Mr. Moyes was a director of Integrated Diagnostics, Inc., a privately held molecular diagnostics company from March 2011 to November 2016. Mr. Moyes was a member of the board of directors of Osiris Therapeutics, Inc., a public bio-surgery company, from May 2006 until December 2017 and Amedica Corporation, a public orthopedic implant company, from November 2012 to August 2014. He served as Chief Financial Officer of Amedica from October 2013 to August 2014 where he was responsible for developing and executing the company’s financial strategy. From May 2008 through July 2009 Mr. Moyes served as the Chief Financial Officer of XDx, Inc. now CareDx, Inc., a privately held molecular diagnostics company. In that role, he orchestrated the company’s right-sizing strategy. Prior to that, Mr. Moyes served as the Chief Financial Officer of Myriad Genetics, Inc., a public healthcare diagnostics company, from June 1996 until November 2007 and as its Vice President of Finance from July 1993 until May 1996 where he led the financial team as it transitioned from a small private company to a publicly held enterprise. From 1991 to 1993 Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. In that role he established the company’s financial infrastructure. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991 most recently as a Senior Manager. At KPMG LLP, he was primarily responsible for conducting financial audits of high-tech and biotech clients. Mr. Moyes also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 through 2006. He holds an M.B.A. from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certified Public Accountant.
- Cindy Jacobs
-
Cindy Jacobs，自2008年8月起任我公司执行副总裁及首席医疗官，2005年9月至2008年8月任OncoGenex Technologies有限公司的执行副总裁兼首席医疗官。1999年至2005年7月，她是科雷莎公司（Corixa Corporation）的首席医疗官及临床发展高级副总裁。在1999年之前，他担任两家其他生物制药公司的临床研究副总裁。她持有华盛顿州立大学（Washington State University）兽医病理学/微生物博士学位和华盛顿大学（University of Washington）医学院医学博士学位。
Cindy Jacobs has served as our President since September 2020 and our Chief Medical Officer since August 2008 and a member of the Board of Directors since March 2021. Previously, Dr. Jacobs served as Executive Vice President and Chief Medical Officer of OncoGenex Pharmaceuticals, Inc. from September 2005 to August 2008. Dr. Jacobs is also the founder of Eagles Ridge Executive Consulting LLC., an executive consulting business operating since July 2020. From 1999 to July 2005 Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999 Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs has served on the Board of Directors of Renown Pharma Limited since January 2018 and Pacylex Pharmaceuticals Inc. since October 2020. Dr. Jacobs received her Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School. - Cindy Jacobs，自2008年8月起任我公司执行副总裁及首席医疗官，2005年9月至2008年8月任OncoGenex Technologies有限公司的执行副总裁兼首席医疗官。1999年至2005年7月，她是科雷莎公司（Corixa Corporation）的首席医疗官及临床发展高级副总裁。在1999年之前，他担任两家其他生物制药公司的临床研究副总裁。她持有华盛顿州立大学（Washington State University）兽医病理学/微生物博士学位和华盛顿大学（University of Washington）医学院医学博士学位。
- Cindy Jacobs has served as our President since September 2020 and our Chief Medical Officer since August 2008 and a member of the Board of Directors since March 2021. Previously, Dr. Jacobs served as Executive Vice President and Chief Medical Officer of OncoGenex Pharmaceuticals, Inc. from September 2005 to August 2008. Dr. Jacobs is also the founder of Eagles Ridge Executive Consulting LLC., an executive consulting business operating since July 2020. From 1999 to July 2005 Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999 Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs has served on the Board of Directors of Renown Pharma Limited since January 2018 and Pacylex Pharmaceuticals Inc. since October 2020. Dr. Jacobs received her Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School.
- Martin Mattingly
-
Martin Mattingly，制药学博士，自2010年6月起任董事。他自2010年8月起任Tech Coast Angels的成员。先前，他从2007年11月起在一家生物制药公司 Trimeris有限公司担任首席执行官，直到该公司于2011年11月和 Synageva合并。他从2007年11月至2011年11月在Trimeris有限公司的董事会任职。2005年至2007年，他受雇于一家生物制药公司 Ambrx有限公司，在此他担任总裁兼首席执行官。2003年至2005年，他担任一家生物技术公司CancerVax Corporation的执行副总裁兼首席营运官。1996年至2003年，他在Agouron Pharmaceutical有限公司和辉瑞公司（Pfizer, Inc.）的许多管理职务上展现其高级领导力，包括担任Agouron HIV分部的总经理，辉瑞公司的产品开发组副总裁和辉瑞的全球营销计划副总裁。他持有肯塔基大学（University of Kentucky）制药学博士学位。
Martin Mattingly has served as a director since June 2010. Since December 2014 Dr. Mattingly has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007 Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005 Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003 he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky. - Martin Mattingly，制药学博士，自2010年6月起任董事。他自2010年8月起任Tech Coast Angels的成员。先前，他从2007年11月起在一家生物制药公司 Trimeris有限公司担任首席执行官，直到该公司于2011年11月和 Synageva合并。他从2007年11月至2011年11月在Trimeris有限公司的董事会任职。2005年至2007年，他受雇于一家生物制药公司 Ambrx有限公司，在此他担任总裁兼首席执行官。2003年至2005年，他担任一家生物技术公司CancerVax Corporation的执行副总裁兼首席营运官。1996年至2003年，他在Agouron Pharmaceutical有限公司和辉瑞公司（Pfizer, Inc.）的许多管理职务上展现其高级领导力，包括担任Agouron HIV分部的总经理，辉瑞公司的产品开发组副总裁和辉瑞的全球营销计划副总裁。他持有肯塔基大学（University of Kentucky）制药学博士学位。
- Martin Mattingly has served as a director since June 2010. Since December 2014 Dr. Mattingly has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007 Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005 Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003 he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky.
高管简历
中英对照 | 中文 | 英文- John Bencich
John Bencich，2014年8月以来，他一直担任我们的副总裁兼首席财务官。加入我们之前，他曾任职Integrated Diagnostics公司（分子诊断公司），在那里他担任首席财务官（从2012年9月到2014年8月）。加入Integrated Diagnostics公司之前，他曾担任Allozyne公司的首席财务官（2011年7月以来）。他曾担任独立顾问（2010年11月至加入Allozyne公司）。他曾担任Trubion Pharmaceuticals公司（生物科技公司）的副总裁、首席财务官、财务主管（从2009年11月到2010年10月公司被Emergent BioSolutions公司收购）。他曾担任Trubion公司的高级财务会计董事（2007年5月至2009年11月）。2004年9月至2007年4月，他曾任职Onyx Software Corporation（软件公司），在那里他最后担任财务主管兼公司总会计师。从1999年到2004年，他曾担任Ernst & Young公司（国际专业服务公司）的职员，在那里他最后担任经理。他持有the University of San Diego的会计学士学位，以及Seattle University的工商管理硕士学位。他持有the State of Washington的注册会计师执照，目前拥有一个活跃的许可证。
John Bencich has served as our Chief Executive Officer and member of the Board of Directors since September 2020. Previously, Mr. Bencich served as our Vice President and Chief Financial Officer since August 2014 and as our Executive Vice President and Chief Operating Officer since August 2017. Mr. Bencich joined us from Integrated Diagnostics, Inc., a molecular diagnostics company, where he served as Chief Financial Officer from September 2012 to August 2014. Prior to joining Integrated Diagnostics, he served as Chief Financial Officer of Allozyne, Inc. since July 2011. Mr. Bencich was an independent consultant from November 2010 until he joined Allozyne. He served as the Vice President, Chief Financial Officer and Treasurer of Trubion Pharmaceuticals, Inc., a publicly traded biotechnology company, from November 2009 until its acquisition by Emergent BioSolutions Inc. in October 2010. Mr. Bencich served as Trubion’s Senior Director of Finance and Accounting from May 2007 through November 2009. From September 2004 to April 2007 Mr. Bencich was an employee of Onyx Software Corporation, a publicly traded software company, where he last served as Director of Finance and Corporate Controller. From 1999 to 2004 Mr. Bencich was an employee of Ernst & Young LLP, an international professional services firm, where he last served as a manager. Mr. Bencich received a B.A. in Accountancy from the University of San Diego and an M.B.A. from Seattle University. Mr. Bencich received his Certified Public Accountant Certification from the State of Washington and held an active license for 17 years.- John Bencich，2014年8月以来，他一直担任我们的副总裁兼首席财务官。加入我们之前，他曾任职Integrated Diagnostics公司（分子诊断公司），在那里他担任首席财务官（从2012年9月到2014年8月）。加入Integrated Diagnostics公司之前，他曾担任Allozyne公司的首席财务官（2011年7月以来）。他曾担任独立顾问（2010年11月至加入Allozyne公司）。他曾担任Trubion Pharmaceuticals公司（生物科技公司）的副总裁、首席财务官、财务主管（从2009年11月到2010年10月公司被Emergent BioSolutions公司收购）。他曾担任Trubion公司的高级财务会计董事（2007年5月至2009年11月）。2004年9月至2007年4月，他曾任职Onyx Software Corporation（软件公司），在那里他最后担任财务主管兼公司总会计师。从1999年到2004年，他曾担任Ernst & Young公司（国际专业服务公司）的职员，在那里他最后担任经理。他持有the University of San Diego的会计学士学位，以及Seattle University的工商管理硕士学位。他持有the State of Washington的注册会计师执照，目前拥有一个活跃的许可证。
- John Bencich has served as our Chief Executive Officer and member of the Board of Directors since September 2020. Previously, Mr. Bencich served as our Vice President and Chief Financial Officer since August 2014 and as our Executive Vice President and Chief Operating Officer since August 2017. Mr. Bencich joined us from Integrated Diagnostics, Inc., a molecular diagnostics company, where he served as Chief Financial Officer from September 2012 to August 2014. Prior to joining Integrated Diagnostics, he served as Chief Financial Officer of Allozyne, Inc. since July 2011. Mr. Bencich was an independent consultant from November 2010 until he joined Allozyne. He served as the Vice President, Chief Financial Officer and Treasurer of Trubion Pharmaceuticals, Inc., a publicly traded biotechnology company, from November 2009 until its acquisition by Emergent BioSolutions Inc. in October 2010. Mr. Bencich served as Trubion’s Senior Director of Finance and Accounting from May 2007 through November 2009. From September 2004 to April 2007 Mr. Bencich was an employee of Onyx Software Corporation, a publicly traded software company, where he last served as Director of Finance and Corporate Controller. From 1999 to 2004 Mr. Bencich was an employee of Ernst & Young LLP, an international professional services firm, where he last served as a manager. Mr. Bencich received a B.A. in Accountancy from the University of San Diego and an M.B.A. from Seattle University. Mr. Bencich received his Certified Public Accountant Certification from the State of Washington and held an active license for 17 years.
- Richard Stewart
Richard Stewart自2017年8月起担任公司董事长、首席执行官和董事。在我们与Achieve Life Science，Inc.合并或合并之前，Stewart先生自2015年5月Achieve Life Science，Inc.成立以来一直担任其董事长兼董事。Stewart自2009年起担任Ricanto Limited（一家制药资产优化公司）创始人和董事。Stewart先生自2016年以来一直担任Renown Pharma Limited的董事长兼首席执行官，该公司是一家专注于帕金森氏症的中枢神经系统公司。在此之前，Stewart先生于2009年担任单一用途中枢神经系统公司Huxley Pharmaceuticals，Inc.的董事长兼首席执行官，在此之前，Huxley Pharmaceuticals，Inc.被Biomarin PharmaceuticalInc.收购Stewart从2013年到2014年担任Brabant Pharma Limited（一家单一目的中枢神经系统公司）首席执行官。从2000年到2007年，他是Amarin Corporation Plc（一家中枢神经系统公司，专注于帕金森氏症和亨廷顿氏症）的联合创始人兼首席执行官。Stewart先生是SkyePharma plc（一家药物输送公司，专门从事控释制剂）的联合创始人和首席财务官，后来担任首席商务官，并从1995年到1998年担任该职位。Stewart先生持有巴斯大学（University of Bath）工商管理理学学士学位。
Richard Stewart has served as our Executive Chairman since September 2020 and our Chairman of the Board, and a director since the consummation of the Merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. in August 2017 the “Merger”. Previously, Mr. Stewart served as Chief Executive Officer from the Merger to September 2020 and was Chairman and a director of Achieve Life Science, Inc., from its founding in May 2015 through the Merger. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009 prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to its acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath.- Richard Stewart自2017年8月起担任公司董事长、首席执行官和董事。在我们与Achieve Life Science，Inc.合并或合并之前，Stewart先生自2015年5月Achieve Life Science，Inc.成立以来一直担任其董事长兼董事。Stewart自2009年起担任Ricanto Limited（一家制药资产优化公司）创始人和董事。Stewart先生自2016年以来一直担任Renown Pharma Limited的董事长兼首席执行官，该公司是一家专注于帕金森氏症的中枢神经系统公司。在此之前，Stewart先生于2009年担任单一用途中枢神经系统公司Huxley Pharmaceuticals，Inc.的董事长兼首席执行官，在此之前，Huxley Pharmaceuticals，Inc.被Biomarin PharmaceuticalInc.收购Stewart从2013年到2014年担任Brabant Pharma Limited（一家单一目的中枢神经系统公司）首席执行官。从2000年到2007年，他是Amarin Corporation Plc（一家中枢神经系统公司，专注于帕金森氏症和亨廷顿氏症）的联合创始人兼首席执行官。Stewart先生是SkyePharma plc（一家药物输送公司，专门从事控释制剂）的联合创始人和首席财务官，后来担任首席商务官，并从1995年到1998年担任该职位。Stewart先生持有巴斯大学（University of Bath）工商管理理学学士学位。
- Richard Stewart has served as our Executive Chairman since September 2020 and our Chairman of the Board, and a director since the consummation of the Merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. in August 2017 the “Merger”. Previously, Mr. Stewart served as Chief Executive Officer from the Merger to September 2020 and was Chairman and a director of Achieve Life Science, Inc., from its founding in May 2015 through the Merger. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009 prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to its acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath.
- Anthony Clarke
Anthony Clarke自2017年8月起担任我们的总裁兼首席科学官兼董事。在合并之前，Clarke博士自2015年起担任Achieve Life Science Inc.的首席科学官，并担任Achieve Life Science，Inc.的董事会成员。Clarke博士自2009年以来是Ricanto Limited的创始人和董事。2016年至今，Clarke博士一直担任Renown Pharma Limited的首席科学官。克拉克博士在2009年赫胥黎制药公司被Biomarin PharmaceuticalInc.收购之前曾担任赫胥黎制药公司的首席科学官在此之前，Clarke博士于2013年至2014年担任Brabant Pharma Limited的首席科学官。Clarke从2008年到2009年担任Alexza UK Ltd.公司秘书和Alexza Pharmaceuticals Inc.（一家医药开发公司）国际开发业务Vice President。Clarke从2005年到2008年担任Amarin Corporation Vice President、临床研究和监管事务。此外，2000年至2004年，Clarke博士担任Cephalon Europe临床和监管事务高级主管，并担任Cephalon，Inc.全球疼痛管理高级主管。Clarke博士在2000年之前曾在其他制药公司担任多个管理职位，以及学术职位和荣誉学术职位。Clarke博士拥有桑德兰大学（University of Sunderland）药理学学士学位和伦敦大学（University of London）精神药理学博士学位。他曾是英国皇家统计学会（Royal Statistics Society UK）的院士，也是英国皇家医学学会（Royal Society of Medicine，UK）的现任院士。
Anthony Clarke has served as our Chief Scientific Officer since August 2017. Previously, Dr. Clarke served as our President and director from August 2017 to September 2020. Prior to the Merger, Dr. Clarke served as Achieve Life Science, Inc.’s Chief Scientific Officer and as a member of Achieve Life Science, Inc.’s Board of Directors since 2015. Dr. Clarke is a founder and director of Ricanto Limited since 2009. From 2016 to the present, Dr. Clarke has been Chief Scientific Officer of Renown Pharma Limited. Dr. Clarke was Chief Scientific Officer of Huxley Pharmaceuticals, Inc. during 2009 prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Prior to Achieve, Dr. Clarke served as Chief Scientific Officer of Brabant Pharma Limited from 2013 to 2014 prior its acquisition by Zogenix Inc. Dr. Clarke served as Company Secretary of Alexza UK Ltd. and as Vice President International Development Operations of Alexza Pharmaceuticals Inc., a pharmaceutical development company, holding both positions from 2008 to 2009. Dr. Clarke served as the Vice President, Clinical Research and Regulatory Affairs at Amarin Corporation from 2005 to 2008. In addition, Dr. Clarke was Senior Director, Clinical and Regulatory Affairs, of Cephalon Europe and as Senior Director, Worldwide Pain Management, of Cephalon, Inc. from 2000 to 2004. Dr. Clarke held a number of management roles in other pharmaceutical companies prior to 2000 as well as academic posts and honorary academic posts. Dr. Clarke holds a Bachelor’s degree in Pharmacology from the University of Sunderland and a Ph.D. in psychopharmacology from the University of London. He was a Fellow of the Royal Statistical Society UK and is a current Fellow of the Royal Society of Medicine (UK).- Anthony Clarke自2017年8月起担任我们的总裁兼首席科学官兼董事。在合并之前，Clarke博士自2015年起担任Achieve Life Science Inc.的首席科学官，并担任Achieve Life Science，Inc.的董事会成员。Clarke博士自2009年以来是Ricanto Limited的创始人和董事。2016年至今，Clarke博士一直担任Renown Pharma Limited的首席科学官。克拉克博士在2009年赫胥黎制药公司被Biomarin PharmaceuticalInc.收购之前曾担任赫胥黎制药公司的首席科学官在此之前，Clarke博士于2013年至2014年担任Brabant Pharma Limited的首席科学官。Clarke从2008年到2009年担任Alexza UK Ltd.公司秘书和Alexza Pharmaceuticals Inc.（一家医药开发公司）国际开发业务Vice President。Clarke从2005年到2008年担任Amarin Corporation Vice President、临床研究和监管事务。此外，2000年至2004年，Clarke博士担任Cephalon Europe临床和监管事务高级主管，并担任Cephalon，Inc.全球疼痛管理高级主管。Clarke博士在2000年之前曾在其他制药公司担任多个管理职位，以及学术职位和荣誉学术职位。Clarke博士拥有桑德兰大学（University of Sunderland）药理学学士学位和伦敦大学（University of London）精神药理学博士学位。他曾是英国皇家统计学会（Royal Statistics Society UK）的院士，也是英国皇家医学学会（Royal Society of Medicine，UK）的现任院士。
- Anthony Clarke has served as our Chief Scientific Officer since August 2017. Previously, Dr. Clarke served as our President and director from August 2017 to September 2020. Prior to the Merger, Dr. Clarke served as Achieve Life Science, Inc.’s Chief Scientific Officer and as a member of Achieve Life Science, Inc.’s Board of Directors since 2015. Dr. Clarke is a founder and director of Ricanto Limited since 2009. From 2016 to the present, Dr. Clarke has been Chief Scientific Officer of Renown Pharma Limited. Dr. Clarke was Chief Scientific Officer of Huxley Pharmaceuticals, Inc. during 2009 prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Prior to Achieve, Dr. Clarke served as Chief Scientific Officer of Brabant Pharma Limited from 2013 to 2014 prior its acquisition by Zogenix Inc. Dr. Clarke served as Company Secretary of Alexza UK Ltd. and as Vice President International Development Operations of Alexza Pharmaceuticals Inc., a pharmaceutical development company, holding both positions from 2008 to 2009. Dr. Clarke served as the Vice President, Clinical Research and Regulatory Affairs at Amarin Corporation from 2005 to 2008. In addition, Dr. Clarke was Senior Director, Clinical and Regulatory Affairs, of Cephalon Europe and as Senior Director, Worldwide Pain Management, of Cephalon, Inc. from 2000 to 2004. Dr. Clarke held a number of management roles in other pharmaceutical companies prior to 2000 as well as academic posts and honorary academic posts. Dr. Clarke holds a Bachelor’s degree in Pharmacology from the University of Sunderland and a Ph.D. in psychopharmacology from the University of London. He was a Fellow of the Royal Statistical Society UK and is a current Fellow of the Royal Society of Medicine (UK).
- Jerry Wan
Jerry Wan自2020年9月起担任我们的首席会计官，自2018年6月起担任我们的会计运营高级总监。他曾于2017年8月至2018年6月担任我们的会计运营总监，并于2014年7月至2017年8月担任OncoGenex Pharmaceuticals，Inc.的会计运营总监。2012年7月至2014年7月，Wan先生担任OncoGenex财务和会计高级经理，并于2011年10月至2012年7月担任财务报告和分析经理。在加入OncoGenex之前，万先生于2010年至2011年担任Gateway Casinos and Entertainment Limited的管理报告经理。从2006年到2010年，Wan先生是国际专业服务公司普华永道会计师事务所（PricewaterhouseCoopers LLP）的员工，在那里他最后一次担任审计和保证集团经理。Wan先生在British Columbia大学获得会计学商业学士学位，并在加拿大特许会计师协会获得特许会计师称号。
Jerry Wan has served as our Principal Accounting Officer since September 2020 and served as our Senior Director, Accounting Operations since June 2018. He previously served as our Director, Accounting Operations from August 2017 to June 2018 and as the Director, Accounting Operations of OncoGenex Pharmaceuticals, Inc. “OncoGenex” from July 2014 to August 2017. From July 2012 to July 2014 Mr. Wan served as OncoGenex’s Senior Manager, Finance and Accounting and, from October 2011 to July 2012 as its Manager, Financial Reporting and Analysis. Prior to joining OncoGenex, Mr. Wan served as Manager, Management Reporting at Gateway Casinos and Entertainment Limited from 2010 to 2011. From 2006 to 2010 Mr. Wan was an employee of PricewaterhouseCoopers LLP, an international professional services firm, where he last served as Manager, Audit and Assurance Group. Mr. Wan received his Bachelor of Commerce in Accounting from The University of British Columbia and a Chartered Accountant Designation from the Canadian Institute of Chartered Accountants.- Jerry Wan自2020年9月起担任我们的首席会计官，自2018年6月起担任我们的会计运营高级总监。他曾于2017年8月至2018年6月担任我们的会计运营总监，并于2014年7月至2017年8月担任OncoGenex Pharmaceuticals，Inc.的会计运营总监。2012年7月至2014年7月，Wan先生担任OncoGenex财务和会计高级经理，并于2011年10月至2012年7月担任财务报告和分析经理。在加入OncoGenex之前，万先生于2010年至2011年担任Gateway Casinos and Entertainment Limited的管理报告经理。从2006年到2010年，Wan先生是国际专业服务公司普华永道会计师事务所（PricewaterhouseCoopers LLP）的员工，在那里他最后一次担任审计和保证集团经理。Wan先生在British Columbia大学获得会计学商业学士学位，并在加拿大特许会计师协会获得特许会计师称号。
- Jerry Wan has served as our Principal Accounting Officer since September 2020 and served as our Senior Director, Accounting Operations since June 2018. He previously served as our Director, Accounting Operations from August 2017 to June 2018 and as the Director, Accounting Operations of OncoGenex Pharmaceuticals, Inc. “OncoGenex” from July 2014 to August 2017. From July 2012 to July 2014 Mr. Wan served as OncoGenex’s Senior Manager, Finance and Accounting and, from October 2011 to July 2012 as its Manager, Financial Reporting and Analysis. Prior to joining OncoGenex, Mr. Wan served as Manager, Management Reporting at Gateway Casinos and Entertainment Limited from 2010 to 2011. From 2006 to 2010 Mr. Wan was an employee of PricewaterhouseCoopers LLP, an international professional services firm, where he last served as Manager, Audit and Assurance Group. Mr. Wan received his Bachelor of Commerce in Accounting from The University of British Columbia and a Chartered Accountant Designation from the Canadian Institute of Chartered Accountants.
- Cindy Jacobs
Cindy Jacobs，自2008年8月起任我公司执行副总裁及首席医疗官，2005年9月至2008年8月任OncoGenex Technologies有限公司的执行副总裁兼首席医疗官。1999年至2005年7月，她是科雷莎公司（Corixa Corporation）的首席医疗官及临床发展高级副总裁。在1999年之前，他担任两家其他生物制药公司的临床研究副总裁。她持有华盛顿州立大学（Washington State University）兽医病理学/微生物博士学位和华盛顿大学（University of Washington）医学院医学博士学位。
Cindy Jacobs has served as our President since September 2020 and our Chief Medical Officer since August 2008 and a member of the Board of Directors since March 2021. Previously, Dr. Jacobs served as Executive Vice President and Chief Medical Officer of OncoGenex Pharmaceuticals, Inc. from September 2005 to August 2008. Dr. Jacobs is also the founder of Eagles Ridge Executive Consulting LLC., an executive consulting business operating since July 2020. From 1999 to July 2005 Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999 Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs has served on the Board of Directors of Renown Pharma Limited since January 2018 and Pacylex Pharmaceuticals Inc. since October 2020. Dr. Jacobs received her Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School.- Cindy Jacobs，自2008年8月起任我公司执行副总裁及首席医疗官，2005年9月至2008年8月任OncoGenex Technologies有限公司的执行副总裁兼首席医疗官。1999年至2005年7月，她是科雷莎公司（Corixa Corporation）的首席医疗官及临床发展高级副总裁。在1999年之前，他担任两家其他生物制药公司的临床研究副总裁。她持有华盛顿州立大学（Washington State University）兽医病理学/微生物博士学位和华盛顿大学（University of Washington）医学院医学博士学位。
- Cindy Jacobs has served as our President since September 2020 and our Chief Medical Officer since August 2008 and a member of the Board of Directors since March 2021. Previously, Dr. Jacobs served as Executive Vice President and Chief Medical Officer of OncoGenex Pharmaceuticals, Inc. from September 2005 to August 2008. Dr. Jacobs is also the founder of Eagles Ridge Executive Consulting LLC., an executive consulting business operating since July 2020. From 1999 to July 2005 Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999 Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs has served on the Board of Directors of Renown Pharma Limited since January 2018 and Pacylex Pharmaceuticals Inc. since October 2020. Dr. Jacobs received her Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School.